On October 22, 2026 Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, reported new data from the ongoing MONSTAR-SCREEN-3 study demonstrating the potential of its whole-genome sequencing (WGS)-based Precise MRD platform to support ultra-sensitive molecular residual disease (MRD) detection in patients with resectable colorectal and pancreatic cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The findings, which will be presented as part of the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, reinforce the role of highly sensitive MRD testing after curative-intent surgery in tumor types where earlier insight into recurrence risk may help inform monitoring and treatment decisions.

"These data reinforce the potential of Precise MRD to bring more sensitive, personalized monitoring to cancers where recurrence can be difficult to identify until disease burden is higher," said Dale Muzzey, Ph.D., Chief Scientific Officer, Myriad Genetics. "By leveraging whole-genome sequencing to build individualized panels capable of detecting ctDNA at very low levels, Precise MRD may help clinicians identify recurrence risk earlier and make more informed decisions about patient management following surgery."

New MONSTAR-SCREEN-3 Data Support Utility of Ultra-Sensitive MRD Detection Across Colorectal and Pancreatic Cancers

The MONSTAR-SCREEN-3 data highlight the performance of Myriad’s WGS-based Precise MRD platform in two high-need settings: resectable colorectal cancer and resectable pancreatic cancer. The study evaluated whether personalized, ultra-sensitive MRD testing could identify patients at higher risk of recurrence following surgery and provide earlier molecular insight than conventional clinical surveillance.

In patients with resectable colorectal cancer, ctDNA detected one month after surgery was strongly associated with disease progression. ctDNA was detected prior to clinical recurrence in all observed recurrence events, with a median lead time of four months. More than half of post-surgical ctDNA-positive patients were identified at ultra-sensitive levels, i.e., below 100 parts per million.

Researchers also reported initial findings in patients with resectable pancreatic cancer, a low-shedding tumor type in which ctDNA detection has historically been challenging. Personalized panel creation was successful for all evaluable patients, with half achieving the maximum 1,000-variant panel. Patients with MRD detected one month after surgery had significantly worse recurrence-free survival than those without detectable MRD, supporting further evaluation of WGS-based MRD testing in this high-need setting.

"Together, these findings add to a growing body of evidence supporting ultra-sensitive MRD detection as a tool to improve post-surgical risk stratification and disease monitoring," said Takayuki Yoshino, MD, PhD, National Cancer Center Hospital East and principal investigator of the MONSTAR-SCREEN-3 study. "The consistent association between post-operative ctDNA detection and patient outcomes, coupled with the ability to identify recurrence months before conventional methods, highlights the potential clinical value of ultra-sensitive MRD assessment for guiding follow-up strategies in patients with resectable cancers."

The MONSTAR-SCREEN-3 findings will be featured in the following ESMO (Free ESMO Whitepaper) presentations:

Clinical Significance of Ultrasensitive ctDNA Detection for Molecular Residual Disease Assessment in Resectable Colorectal Cancer in MONSTAR-SCREEN-3

Session: Proffered Paper 1: Basic Science and Translational Research
Room: Burgos Auditorium – Hall 3
Date: Sunday, October 25, 2026
Time 2:45 -4:15pm

Molecular Residual Disease Detection for Resectable Pancreatic Cancer Using a Whole-Genome Sequencing-Based ctDNA Assay: Initial Findings from MONSTAR-SCREEN-3
Poster Number: 3138P
Date: Sunday, October 25, 2026
Time 12:00 -12:45pm

(Press release, Myriad Genetics, OCT 22, 2026, View Source [SID1234673691])